Abstract: Described are methods and compositions for processes of preparing a radioactive solution of Sn-117m tetraiodide. Aspects include reacting a radioactive solid Sn containing Sn-117m with a solution of I2 in an organic solvent at a temperature and for a duration sufficient to result in the formation of Sn-117m tetraiodide. Then, the organic solvent is removed by evaporation to leave dry Sn-117m tetraiodide. The organic solvent is a low boiling point solvent capable of dissolving I2 and Sn tetraiodide. The organic solvent is selected from the group consisting of an alcohol and a chlorinated solvent. In embodiments may be selected from the group consisting of dichloromethane, trichloromethane, tetrachloromethane, or mixtures thereof. In embodiments, the organic solvent excludes alcohol. The I2 may be in a slight molar excess to the radioactive solid Sn. The method may further include distilling the reactants to remove excess I2 from the distillate.

Abstract: Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.

Abstract: Biological implants have an electroplated surface wherein a substantial portion of the electroplated surface is covered with dendrites. The dendrites assist in maintaining the implant in location. When the metal is a radioactive metal or the surface of the electroplated is coated with a radioactive material, the dendrites increase surface area thereby increasing radiation dosage and further extend the radioactive surface farther away from the surface of the implant, further enhancing radioactive emission. This is particularly useful for a cholangiocarcinoma stent which can be implanted into the biliary stent to treat cholangiocarcinoma.

Abstract: Tin-117m somatoostatin analogs or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analog is also disclosed, as well as novel methods to produce the tin labeled analogs and antagonists.